




BS Nguyễn Phạm Minh Trí Khoa Hồi Sức Sơ Sinh

#### Description of the condition



 newborn inhales mixture of meconium and amniotic fluid into lungs in delivery



#### **Meconium Aspiration: The Statistics**

- ☐ Infants with MEC aspiration syndrome
  - ❖35% need mechanical ventilation

(range 25-60%)

♦12% die (range 5-37%)

#### Management: at present

- Assisted ventilation
- Sedation
- Surfactant
- Nitric oxide
- ECMO
- Circulatory support
- Antibiotics
- **\*** .....

→ Largely SUPPORTIVE

## Remove MEC from the lung: Why NOT ???



# Lung lavage for meconium aspiration syndrome in newborn infants (Review)

Hahn S, Choi HJ, Soll R, Dargaville PA Cochrane Database of Systematic Reviews 2013 Issue 4. Art. No.: CD003486



#### **Objectives**

 Evaluate Effects of LUNG LAVAGE on Morbidity and Mortality in newborn infants with MAS

#### **Search methods**

#### □ Search database:

- Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE, and EMBASE
- up to December 2012
- previous reviews including cross-references, abstracts, conference proceedings; and expert informants

#### Search words:

 meconium aspiration, pulmonary surfactants, bronchoalveolar lavage, lung lavage, pulmonary lavage

#### **Selection criteria**

- Randomised controlled trials that evaluated the effects of lung lavage in infants with MAS
- Lung lavage: intervention in which fluid is instilled into the lung and then removed by suctioning and/or postural drainage
  - Fluids that have been used for this purpose include saline, full-strength and dilute surfactant, and perfluorocarbon
- Standard care: no lavage therapy, but include routine suction of the endotracheal tube to maintain its patency

#### Results of the search

#### □ Twelve studies were excluded:

 Burke-Strickland 1973; Carson 1976; Rosegger 1987; Ogawa 1997; Su 1998; Lam 1999; Schlösser 2002; Kowalska 2002; Chang 2003; Salvia-Roigés 2004; Dargaville 2007; Armenta 2011

#### Four randomised controlled trials were identified

 (Ogawa 1997) was excluded as data on the non lavaged control group were not reported and are not now obtainable

#### Three studies are included in this review

Wiswell 2002; Gadzinowski 2008; Dargaville 2011

#### **Study analysis**

- Type of lavage fluid
  - All included studies used diluted surfactant for lavage
- Lavage aliquot volume
  - ≥ 5 mL/kg in all studies comparing surfactant lavage with standard care
  - ≤ 5 mL/kg in the study comparing surfactant lavage followed by bolus surfactant with surfactant bolus therapy
- Timing of lavage
  - mean age ≥ than six hours in all included studies

Comparison 1

## LUNG LAVAGE VERSUS STANDARD CARE

#### Lung lavage vs. Standard care

- □ Two studies: Dargaville 2011; Wiswell 2002
- Outcomes:
  - Death
  - Use of ECMO
  - Death or Use of ECMO
  - Pneumothorax
  - Indices of pulmonary function: Oxygenation Index, AaDO<sub>2</sub> and PaO<sub>2</sub>/FiO<sub>2</sub>

#### **Outcome 1: Death**

Study or subgroup	Intervention n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Risk Ratio M-H,Fixed,95% CI			
	TIVEN	TIVEN	1-1-1,1 Ked,7576 CI	1 1-1 1,1 1xed,7376 CI			
Wiswell 2002	0/15	0/7		0.0 [ 0.0, 0.0 ]			
Dargaville 2011	3/31	8/35	<del></del>	0.42 [ 0.12, 1.46 ]			
Total (95% CI)	46	42		0.42 0.12, 1.46 ]			
Total events: 3 (Intervention), 8 (Control)							
Heterogeneity: $Chi^2 = 0.0$ , $df = 0$ (P = 1.00); $I^2 = 0.0\%$							
Test for overall effect: $Z = 1.36 (P = 0.17)$							
Test for subgroup differences:	Not applicable						
			0.1 0.2 0.5   2 5 10				


Favours lung lavage

Favours control

#### **Outcome 2: Use of ECMO**

Study or subgroup	Intervention	Control			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,F	xed,95% C			M-H,Fixed,95% CI
Wiswell 2002	1/15	1/7		-			30.5 %	0.47 [ 0.03, 6.43 ]
Dargaville 2011	0/11	3/14	_	-	+		69.5 %	0.18 [ 0.01, 3.13 ]
Total (95% CI)	26	21		-	-		100.0 %	0.27 0.04, 1.86 ]
Total events: 1 (Intervention), 4 (Control)								
Heterogeneity: $Chi^2 = 0.25$ , $df = 1$ (P = 0.62); $I^2 = 0.0\%$								
Test for overall effect: $Z =$	1.33(P = 0.18)							
Test for subgroup difference	es: Not applicable							
			,	ï		ī		
			0.01	0.1	1 10	100		
			Favours lu	ng lavage	Favours	control		


#### **Outcome 3: Death or use of ECMO**



#### **Outcome 4: Pneumothorax**

Study or subgroup	Intervention	Control		F	Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,Fi>	ed,95% CI			M-H,Fixed,95% CI
Wiswell 2002	1/15	0/7		,	•	_	12.4 %	1.50 [ 0.07, 32.84 ]
Dargaville 2011	1/31	5/35	, a	-	-		87.6 %	0.23 [ 0.03, 1.83 ]
Total (95% CI)	46	42		-	-		100.0 %	0.38] 0.08, 1.90]
Total events: 2 (Interventio	on), 5 (Control)							
Heterogeneity: Chi <sup>2</sup> = 1.00	0, df = $I(P = 0.32)$ ; $I^2 = 0$	0%		1				
Test for overall effect: Z =	1.17 P = 0.24							
Test for subgroup differenc	es: Not applicable							
			0.01	0.1	10	100		
			Favours lun	ng lavage	Favours of	control		

#### **Outcome 5: Oxygenation index**



-10

-20


Favours lung lavage

10

Favours control

20


#### Outcome 6: AaDO<sub>2</sub>



Favours lung lavage

Favours control

#### Outcome 7: PaO<sub>2</sub>/FiO<sub>2</sub>



#### **Result Analysis**

- Lung lavage has effect in all outcomes, but only these are significant in statistics:
  - Outcome 3: Death or Use of ECMO
  - Outcome 5: Oxygenation index at 48 hours


Comparison 2

# LUNG LAVAGE FOLLOWED BY SURFACTANT BOLUS VERSUS SURFACTANT BOLUS


### Lung lavage followed by surfactant bolus vs. surfactant bolus

- □ One study: Gadzinowski 2008
- Outcomes:
  - Death
  - Pneumothorax

#### **Outcome 1: Death**



#### **Outcome 2: Pneumothorax**



#### **Authour's conclusion**

- □ In infants with MAS, lung lavage with diluted surfactant may be beneficial (Grade 2B)
  - A Grade 2 recommendation is a weak recommendation. It means "this is our suggestion, but you may want to think about it". For Grade 2 recommendations, benefits and risks may be finely balanced, or uncertain.
  - Grade B evidence is evidence from randomized trials with important limitations, or very strong evidence of some other form.

#### **Authour's conclusion**

- Additional controlled clinical trials of lavage therapy should be conducted to
  - confirm the treatment effect
  - refine the method of lavage treatment
  - compare lavage treatment with other approaches, including surfactant bolus therapy
- Long-term outcomes should be evaluated in further clinical trials

# THANK YOU FOR WATCHING!